

18. A method of preventing or treating transplant-induced disorders comprising administering a therapeutically effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal, wherein the 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide is present in free form or in pharmaceutically acceptable salt form.

19. The method of claim 18 wherein the transplant-induced disorders is obliterative bronchiolitis.

20. A method of preventing the invasion of cells by bacteria comprising administering a therapeutically effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal, wherein the 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide is present in free form or in pharmaceutically acceptable salt form.

21. The method of claim 20 wherein the bacteria is *Porphyromonas gingivalis*.

B | 22. A method of preventing or treating restenosis comprising administering a therapeutically effective amount of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal.

23. A method of preventing or treating atherosclerosis comprising administering a therapeutically effective amount of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal.

24. A method of preventing or treating transplant-induced disorders comprising administering a therapeutically effective amount of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal.

25. The method of claim 18 wherein the transplant-induced disorders is obliterative bronchiolitis.

26. A method of preventing the invasion of cells by bacteria comprising administering a therapeutically effective amount of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal.

27. The method of claim 20 wherein the bacteria is *Porphyromonas gingivalis*.

28. A method of preventing or treating restenosis comprising administering a therapeutically effective amount of the β -crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal.

29. A method of preventing or treating atherosclerosis comprising administering a therapeutically effective amount of the β -crystal form of the methanesulfonic acid salt of 4-(4-

methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal.

30. A method of preventing or treating transplant-induced disorders comprising administering a therapeutically effective amount of the β -crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal.

31. The method of claim 18 wherein the transplant-induced disorders is obliterative bronchiolitis.

32. A method of preventing the invasion of cells by bacteria comprising administering a therapeutically effective amount of the β -crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal.

33. The method of claim 20 wherein the bacteria is Porphyromonas gingivalis.

34. A method of preventing or treating restenosis comprising administering a therapeutically effective amount of the α -crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal.

35. A method of preventing or treating atherosclerosis comprising administering a therapeutically effective amount of the α -crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal.

36. A method of preventing or treating transplant-induced disorders comprising administering a therapeutically effective amount of the α -crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal.

37. The method of claim 18 wherein the transplant-induced disorders is obliterative bronchiolitis.

38. A method of preventing the invasion of cells by bacteria comprising administering a therapeutically effective amount of the α -crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal.

39. The method of claim 20 wherein the bacteria is Porphyromonas gingivalis.

40. A pharmaceutical composition comprising 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide and a pharmaceutically acceptable carrier.

41. A pharmaceutical composition comprising the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide and a pharmaceutically acceptable carrier.